HALO - Halozyme Therapeutics Inc.
IEX Last Trade
63.82
0.080 0.125%
Share volume: 959,677
Last Updated: Fri 30 Aug 2024 09:59:53 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$63.74
0.08
0.13%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-09 | 2022-11-08 | 2023-02-21 | 2023-05-09 | 2023-08-08 | 2023-11-06 | 2024-02-20 | 2024-05-07 | |
| Assets | |||||||||
| Total Assets | 1.781 B | 1.865 B | 1.842 B | 1.699 B | 1.810 B | 1.893 B | 1.733 B | 1.842 B | |
| Current Assets | 541.938 M | 653.201 M | 739.013 M | 615.019 M | 765.745 M | 879.006 M | 746.424 M | 873.584 M | |
| Inventories | 97.615 M | 103.276 M | 100.123 M | 107.521 M | 132.406 M | 128.921 M | 127.601 M | 168.541 M | |
| Other Current Assets | 45.595 M | 51.039 M | 45.024 M | 37.007 M | 38.885 M | 49.478 M | 48.613 M | 45.690 M | |
| Short Term Investments | 45.595 M | 51.039 M | 45.024 M | 37.007 M | 38.885 M | 49.478 M | 48.613 M | 45.690 M | |
| Total Receivables | 189.368 M | 233.302 M | 231.072 M | 194.883 M | 246.179 M | 217.325 M | 234.210 M | 195.902 M | |
| Current Cash | 209.360 M | 265.584 M | 362.794 M | 275.608 M | 348.275 M | 483.282 M | 336.000 M | 463.451 M | |
| Total Non-current Assets | 1.239 B | 1.211 B | 1.102 B | 1.084 B | 1.045 B | 1.014 B | 986.846 M | 967.943 M | |
| Property Plant Equipment | 31.368 M | 31.068 M | 35.101 M | 38.544 M | 36.050 M | 37.466 M | 74.944 M | 41.886 M | |
| Other Assets | 26.283 M | 25.783 M | 26.301 M | 25.240 M | 18.409 M | 18.115 M | 17.816 M | 17.319 M | |
| Intangible Assets | 976.097 M | 948.904 M | 546.652 M | 528.817 M | 510.982 M | 490.641 M | 472.879 M | 455.116 M | |
| Goodwill | 199.481 M | 199.481 M | 409.049 M | 416.223 M | 416.821 M | 416.821 M | 416.821 M | 416.821 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.781 B | 1.865 B | 1.842 B | 1.699 B | 1.810 B | 1.893 B | 1.733 B | 1.842 B | |
| Total liabilities | 1.488 B | 1.768 B | 1.672 B | 1.634 B | 1.659 B | 1.643 B | 1.649 B | 1.664 B | |
| Total current liabilities | 199.512 M | 109.384 M | 130.789 M | 91.919 M | 116.393 M | 115.185 M | 112.494 M | 131.639 M | |
| Accounts Payable | 12.232 M | 18.166 M | 17.693 M | 8.695 M | 10.120 M | 19.318 M | 11.816 M | 13.325 M | |
| Other liabilities | 138.290 M | 138.023 M | 48.158 M | 47.298 M | 47.016 M | 30.675 M | 37.720 M | 31.201 M | |
| Current long term debt | 99.048 M | 13.315 M | 13.334 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 1.147 B | 1.491 B | 1.493 B | 1.494 B | 1.496 B | 1.498 B | 1.499 B | 1.501 B | |
| Other liabilities | 138.290 M | 138.023 M | 48.158 M | 47.298 M | 47.016 M | 30.675 M | 37.720 M | 31.201 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 293.171 M | 96.991 M | 169.798 M | 65.850 M | 151.033 M | 249.181 M | 83.808 M | 177.808 M | |
| Common stock | 137.937 M | 136.527 M | 135.254 M | 135.027 M | 131.730 M | 131.965 M | 128.986 M | 126.941 M | |
| Retained earnings | 23.881 M | 85.515 M | 143.217 M | 65.694 M | 140.448 M | 222.285 M | 90.550 M | 167.373 M |